Maximum efficacy of finasteride is obtained within 6 months and maintained over 6 years - Follow-up of the Scandinavian open-extension study

被引:27
作者
Ekman, P [1 ]
机构
[1] Karolinska Hosp, Dept Urol, S-17671 Stockholm, Sweden
关键词
benign prostatic hyperplasia; finasteride; long-term efficiency;
D O I
10.1159/000019566
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To study the long-term efficacy and safety of the drug finasteride (Proscar(R)) for benign prostatic hyperplasia and to evaluate whether an improved effect beyond 1 year was due to continuous selection of 'responders', We also wanted to investigate whether drop-outs differed in short-term responses to those completing the trial, Methods: A total of 182 patients were enrolled in a double-blind randomized multicenter study with the drug finasteride. After 6 months, all patients were treated with active drug for up to 6 years, Ninety-nine of the patients (54.5%) were still in the trial at its closure. Results: Patients treated with active drug had a decrease in prostate size of around 27% at 6 months, a figure reached by the ex-placebo group at 12 months. At 6 years, both groups had a reduction in prostate size of 21% as measured from baseline, At 6 months, urinary flow had improved by a mean of 2.4 ml/s in the finasteride group and reached an improvement of 2.8 ml/s in the ex-placebo group at 12 months, At 6 years, the flow had improved by 2.2 ml/s in both groups combined as compared to baseline data, The symptom score was improved by 3.4 points in the finasteride group at 6 months and by 2.6 points in the ex-placebo group at 12 months; both values were then maintained over 6 years. Conclusion: In responders (those completing the 6-year trial), finasteride appeared to be a safe drug which reduced the prostate size by 20-25% within 6 months, with a simultaneous 30% improvement of objective and subjective symptoms and a 2.2 ml/s improvement in urinary flow rate, The improvements were maintained for at least 6 years; however, further improvement beyond 6 months of therapy was not likely to occur.
引用
收藏
页码:312 / 317
页数:6
相关论文
共 11 条
[1]  
BEISLAND HO, 1992, EUR UROL, V22, P271
[2]  
Boyarsky S, 1976, Trans Am Assoc Genitourin Surg, V68, P29
[3]   Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials [J].
Boyle, P ;
Gould, AL ;
Roehrborn, CG .
UROLOGY, 1996, 48 (03) :398-405
[4]  
BRUCHOVSKY N, 1968, J BIOL CHEM, V243, P2012
[5]   PLACEBO-CONTROLLED DOUBLE-BLIND-STUDY OF EFFECT OF PHENOXYBENZAMINE IN BENIGN PROSTATIC OBSTRUCTION [J].
CAINE, M ;
PERLBERG, S ;
MERETYK, S .
BRITISH JOURNAL OF UROLOGY, 1978, 50 (07) :551-554
[6]  
*FIN STUD GROUP, 1993, PROSTATE, V22, P292
[7]   THE EFFECT OF FINASTERIDE IN MEN WITH BENIGN PROSTATIC HYPERPLASIA [J].
GORMLEY, GJ ;
STONER, E ;
BRUSKEWITZ, RC ;
IMPERATOMCGINLEY, J ;
WALSH, PC ;
MCCONNELL, JD ;
ANDRIOLE, GL ;
GELLER, J ;
BRACKEN, BR ;
TENOVER, JS ;
VAUGHAN, ED ;
PAPPAS, F ;
TAYLOR, A ;
BINKOWITZ, B ;
NG, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (17) :1185-1191
[8]   LONG-TERM EFFICACY AND SAFETY OF TERAZOSIN IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA [J].
LEPOR, H .
UROLOGY, 1995, 45 (03) :406-413
[9]   THE ALPHA-ADRENERGIC BINDING-PROPERTIES OF TERAZOSIN IN THE HUMAN-PROSTATE ADENOMA AND CANINE BRAIN [J].
LEPOR, H ;
BAUMANN, M ;
SHAPIRO, E .
JOURNAL OF UROLOGY, 1988, 140 (03) :664-667
[10]  
MOORE E, 1995, EUR UROL, V28, P304